3.9 Article

Management of overweight and obese patients with coronary heart disease across Europe

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1097/HJR.0b013e328336a05f

关键词

coronary heart disease; obesity; secondary prevention

资金

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. GlaxoSmithKline
  4. Pfizer
  5. Sanofi-Aventis
  6. Servier
  7. Merck/Schering-Plough
  8. Novartis

向作者/读者索取更多资源

Aims Several studies have reported increasing obesity rates in the general population. Using data from the EUROASPIRE III survey, we investigated as to what extent the obesity epidemic affects the high priority group of coronary heart disease patients. Methods and results Data from 8924 patients, who had experienced a recent coronary acute event, from 22 countries in Europe participating in the EUROASPIRE III study were gathered in 2006- 2007. Eight centres had also participated in the earlier two EUROASPIRE surveys carried out in 1994- 1995 and 1999- 2000. In these eight centres, obesity prevalence in coronary patients had increased from 25 to 38% during the past decade. The most recent survey shows that obesity is more prevalent in women ( 45 vs. 32% in men) and is a major health problem across all the 22 countries. Only 18% of all the patients were found to reach a body mass index below 25 kg/m(2) whereas 53% were diagnosed with central obesity. Since their hospital discharge, only half of the obese patients reported to have followed the dietary recommendations and 48% reported engagement in more physical activity. Only 13% of the patients who were overweight at the time of the coronary event reached the target of >= 5% weight loss whereas 21% of them presented with a weight gain of 5% or more. Conclusion The prevalence of obesity is still increasing and reaching epidemic proportions in the high priority group of coronary patients all over Europe. Patients' awareness and current management of obesity seems inadequate. More intensive programs focusing on diet and especially physical activity are urgently required. Eur J Cardiovasc Prev Rehabil 17:447-454 (C) 2010 The European Society of Cardiology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据